Premium
Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P 1 receptor modulator, in the first‐in‐human study
Author(s) -
Brossard Patrick,
Derendorf Hartmut,
Xu Jian,
Maatouk Haidar,
Halabi Atef,
Dingemanse Jasper
Publication year - 2013
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.12129
Subject(s) - pharmacokinetics , pharmacodynamics , pharmacology , tolerability , medicine , placebo , crossover study , adverse effect , pathology , alternative medicine
Aims This study investigated the tolerability, safety, pharmacokinetics and pharmacodynamics of ponesimod, a novel oral selective sphingosine‐1‐phosphate ( S1P 1 ) receptor modulator in development for the treatment of auto‐immune diseases. Methods This was a double‐blind, placebo‐controlled, ascending, single‐dose study. Healthy male subjects received doses of 1–75 mg or placebo control. Results Ponesimod was well tolerated. Starting with a dose of 8 mg, transient asymptomatic reductions in heart rate were observed. Ponesimod pharmacokinetics were dose proportional. The median time to maximal concentration ranged from 2.0 to 4.0 h, and ponesimod was eliminated with a mean half‐life varying between 21.7 and 33.4 h. Food had a minimal effect on ponesimod pharmacokinetics. Doses of ≥8 mg reduced total lymphocyte count in a dose‐dependent manner. Lymphocyte counts returned to normal ranges within 96 h. A pharmacokinetic/pharmacodynamic model was developed that adequately described the observed effects of ponesimod on total lymphocyte counts. Conclusions Single doses of ponesimod up to and including 75 mg were well tolerated. The results of this ascending single‐dose study indicate an immunomodulator potential for ponesimod and a pharmacokinetic/pharmacodynamic profile consistent with once‐a‐day dosing.